Treatment
Gecacitinib clinical trials
We’re tracking 7 recruiting studies that include Gecacitinib, each written for real people, not researchers, below.
Recruiting studies
- NCT06883526RecruitingPhase 1/Phase 2
ZG005 plus gecacitinib for lymphoma that has returned or not responded
This trial tests a combination of two drugs, ZG005 and gecacitinib, for people with lymphoma that has come back or hasn't gotten better with prior treatment. The goal is to see if this combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT06903377RecruitingPhase 1/Phase 2
ZG005 plus Gecacitinib for advanced lung cancer
This trial tests a new combination of two drugs, ZG005 and Gecacitinib, for people with advanced non-small cell lung cancer that cannot be treated with surgery or radiation. The goal is to see if the combination can shrink or slow the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07012304RecruitingPhase 1/Phase 2
Testing gecacitinib for chronic graft-versus-host disease after 2 or more treatments
This trial tests a new drug, gecacitinib, for patients with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after 2 to 5 prior treatments. It aims to see if the drug is safe and effective.
BeijingAges 18 years+ - NCT07080216RecruitingPhase 1/Phase 2
Study of ZG005 and Gecacitinib for advanced cervical cancer
This trial tests a combination of two new drugs, ZG005 and Gecacitinib, for people with advanced cervical cancer that has spread or come back. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18–75 - NCT07445893Recruiting
Study of gecacitinib plus pegylated interferon for polycythemia vera
This trial tests a combination of two drugs—gecacitinib (a JAK inhibitor) and pegylated interferon—to see if they work better together for people with polycythemia vera (PV), a blood cancer that causes too many red blood cells. The study is for patients who have not tried these specific treatments before and who have symptoms like high blood counts, weight loss, night sweats, or an enlarged spleen.
BeijingAges 18 years+ - NCT07285889RecruitingPhase 1/Phase 2
Jaktinib as first treatment for acute graft-versus-host disease
This trial tests a new pill called jaktinib for people who develop moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if adding jaktinib to standard steroid therapy can better control the disease.
Hangzhou, ZhejiangAges 18 years+ - NCT07454226Recruiting
Drug combo for Ph-like acute lymphoblastic leukemia
This trial tests a combination of targeted drugs (ABL/JAK inhibitors) with chemotherapy and venetoclax for people with a type of leukemia called Ph-like ALL. It aims to see if this treatment is safe and effective.
Tianjin, Tianjin MunicipalityAges 14–60
What Gecacitinib is being studied for
Conditions with recruiting Gecacitinib studies.
Common questions
- Are there clinical trials studying Gecacitinib?
- Yes. Clin2 currently lists 7 recruiting studies that include Gecacitinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Gecacitinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Gecacitinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Gecacitinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.